Increased NAD+ concomitant with IDO induction in human tumor cells may enhances PARP activity and resistance to PARP inhibitors (among multiple NAD+ roles [39] including NAD+-mediated resistance to reactive oxygen stress [40]). Here, IDO1 is linked to neoplasm.